0.00Open0.09Pre Close0 Volume509 Open Interest55.00Strike Price0.00Turnover474.06%IV19.85%PremiumMay 9, 2025Expiry Date0.00Intrinsic Value100Multiplier0DDays to Expiry0.09Extrinsic Value100Contract SizeAmericanOptions Type-0.0279Delta0.0079Gamma761.22Leverage Ratio-1.0704Theta0.0000Rho-21.22Eff Leverage0.0011Vega
AstraZeneca Stock Discussion
First Major Breakthrough in 10 Years: ENHERTU Combo Outperforms Standard HER2+ Breast Cancer Treatment
First Major Breast Cancer Treatment Breakthrough in 10 Years: ENHERTU Trial Reveals Superior Efficacy
Revolutionary AI Technology Detects Lung Cancer Mutations Without Invasive Testing
New Breast Cancer Drug DATROWAY Shows 37% Better Survival Rates in EU Approval
Gapping Up
$Diageo (DEO.US)$ shares rose 4.6% in pre-market trading, as U.S. tariffs avoided the worst-case scenario for spirits. Goodbody noted no new duties on Canadian and Mexican imports, while Jefferies highlighted the avoidance of a potential 200% tariff on EU alcohol, benefiting European distillers.
Pharmaceutical shares are up in pre-market trading as drug imports could be exempt from the new 'reciprocal ta...
Breakthrough: First-Ever FDA-Approved Immunotherapy Shows 32% Better Outcomes in Bladder Cancer
Major Breakthrough: AstraZeneca's TAGRISSO Extends Lung Cancer Survival to Nearly 5 Years
ENHERTU Shows 38% Reduced Death Risk in Breast Cancer - EU Approval Now One Step Closer
Can This Breakthrough Breast Cancer Drug Transform AstraZeneca's Oncology Portfolio?
No comment yet